Market closedNon-fractional

MacroGenics/MGNX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About MacroGenics

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).

Ticker

MGNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Rockville, United States

Employees

339

MacroGenics Metrics

BasicAdvanced
$263M
Market cap
-
P/E ratio
-$0.38
EPS
2.08
Beta
-
Dividend rate
$263M
2.08
3.633
3.433
28.192
32.04
-96.26%
-38.77%
-21.58%
6.011
2.46
2.46
-2.288
-73.78%
-74.28%
-26.25%
-46.59%

What the Analysts think about MacroGenics

Analyst Ratings

Majority rating from 12 analysts.
Buy

MacroGenics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-572.52% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.1M
-14.95%
Net income
-$52M
13.26%
Profit margin
-572.52%
33.18%

MacroGenics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 30.67%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.92
$0.28
-$0.75
-$0.84
-
Expected
-$0.52
-$0.10
-$0.15
-$0.64
-$0.63
Surprise
-276.51%
-392.89%
387.96%
30.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for MacroGenics stock?

MacroGenics (MGNX) has a market cap of $263M as of July 06, 2024.

What is the P/E ratio for MacroGenics stock?

The price to earnings (P/E) ratio for MacroGenics (MGNX) stock is 0 as of July 06, 2024.

Does MacroGenics stock pay dividends?

No, MacroGenics (MGNX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next MacroGenics dividend payment date?

MacroGenics (MGNX) stock does not pay dividends to its shareholders.

What is the beta indicator for MacroGenics?

MacroGenics (MGNX) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell MacroGenics stock

Buy or sell MacroGenics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing